Variation in global transurethral resection of bladder tumour practice: early results from the RESECT study.
BAUS ePoster online library. Gallagher K. 06/22/21; 318998; p10-1
Disclosure(s): The RESECT study/ BURST are in receipt of unrestricted grants from Karl Storz and Photocure.
Mr. Kevin Gallagher
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
Introduction
The aim of this study was to describe differences in hospital-level TURBT practice across the world.
Patients & Methods
The RESECT study (transurethral REsection and Single-instillation intravesical chemotherapy Evaluation (SI-IVC) in bladder Cancer Treatment) is an international observational study. In the first phase of the study, lead collaborators at registered hospitals were asked to complete a web-based questionnaire about usual practice at their hospital.
Results
The survey was completed in 182 hospitals from 40 countries (Table 1). The median number of urologists routinely performing TURBT per hospital was 6.5 (25th, 75th: 4-9). The median number of weekly TURBTs performed for 'first' bladder tumours, per hospital was 3 (25th, 75th: 2-5). In all, 58/179 (32.4%) hospitals utilised dedicated TURBT surgical lists.
Given the option of 'usually' 'sometimes' or 'never', 78/176 (44.3%) usually used bipolar, and 106/176 (60.2%) monopolar, resecting loop for TURBT. 38/176 (22%) hospitals used holmium and 9/176 (5.1%) used thulium laser 'usually' or 'sometimes'. Fractionated resection was performed 'usually' in most hospitals (118/176 (67%)), whilst 20/176 (11.4%) 'usually' performed en-bloc resection. Photodynamic Diagnosis assisted resection and narrow band imaging were used for first tumour resections in 36/176 (20.5%) and 45/176 (25.6%) respectively.
Regional trends were observed, examples of these are summarised in table 1.
Conclusions
There is observed variation in the organisation of services, technical performance and audit systems related to TURBT surgery across the world. It is not known how these differences impact outcomes, and this will be explored in the next phase of the RESECT study.
The aim of this study was to describe differences in hospital-level TURBT practice across the world.
Patients & Methods
The RESECT study (transurethral REsection and Single-instillation intravesical chemotherapy Evaluation (SI-IVC) in bladder Cancer Treatment) is an international observational study. In the first phase of the study, lead collaborators at registered hospitals were asked to complete a web-based questionnaire about usual practice at their hospital.
Results
The survey was completed in 182 hospitals from 40 countries (Table 1). The median number of urologists routinely performing TURBT per hospital was 6.5 (25th, 75th: 4-9). The median number of weekly TURBTs performed for 'first' bladder tumours, per hospital was 3 (25th, 75th: 2-5). In all, 58/179 (32.4%) hospitals utilised dedicated TURBT surgical lists.
Given the option of 'usually' 'sometimes' or 'never', 78/176 (44.3%) usually used bipolar, and 106/176 (60.2%) monopolar, resecting loop for TURBT. 38/176 (22%) hospitals used holmium and 9/176 (5.1%) used thulium laser 'usually' or 'sometimes'. Fractionated resection was performed 'usually' in most hospitals (118/176 (67%)), whilst 20/176 (11.4%) 'usually' performed en-bloc resection. Photodynamic Diagnosis assisted resection and narrow band imaging were used for first tumour resections in 36/176 (20.5%) and 45/176 (25.6%) respectively.
Regional trends were observed, examples of these are summarised in table 1.
Conclusions
There is observed variation in the organisation of services, technical performance and audit systems related to TURBT surgery across the world. It is not known how these differences impact outcomes, and this will be explored in the next phase of the RESECT study.
Introduction
The aim of this study was to describe differences in hospital-level TURBT practice across the world.
Patients & Methods
The RESECT study (transurethral REsection and Single-instillation intravesical chemotherapy Evaluation (SI-IVC) in bladder Cancer Treatment) is an international observational study. In the first phase of the study, lead collaborators at registered hospitals were asked to complete a web-based questionnaire about usual practice at their hospital.
Results
The survey was completed in 182 hospitals from 40 countries (Table 1). The median number of urologists routinely performing TURBT per hospital was 6.5 (25th, 75th: 4-9). The median number of weekly TURBTs performed for 'first' bladder tumours, per hospital was 3 (25th, 75th: 2-5). In all, 58/179 (32.4%) hospitals utilised dedicated TURBT surgical lists.
Given the option of 'usually' 'sometimes' or 'never', 78/176 (44.3%) usually used bipolar, and 106/176 (60.2%) monopolar, resecting loop for TURBT. 38/176 (22%) hospitals used holmium and 9/176 (5.1%) used thulium laser 'usually' or 'sometimes'. Fractionated resection was performed 'usually' in most hospitals (118/176 (67%)), whilst 20/176 (11.4%) 'usually' performed en-bloc resection. Photodynamic Diagnosis assisted resection and narrow band imaging were used for first tumour resections in 36/176 (20.5%) and 45/176 (25.6%) respectively.
Regional trends were observed, examples of these are summarised in table 1.
Conclusions
There is observed variation in the organisation of services, technical performance and audit systems related to TURBT surgery across the world. It is not known how these differences impact outcomes, and this will be explored in the next phase of the RESECT study.
The aim of this study was to describe differences in hospital-level TURBT practice across the world.
Patients & Methods
The RESECT study (transurethral REsection and Single-instillation intravesical chemotherapy Evaluation (SI-IVC) in bladder Cancer Treatment) is an international observational study. In the first phase of the study, lead collaborators at registered hospitals were asked to complete a web-based questionnaire about usual practice at their hospital.
Results
The survey was completed in 182 hospitals from 40 countries (Table 1). The median number of urologists routinely performing TURBT per hospital was 6.5 (25th, 75th: 4-9). The median number of weekly TURBTs performed for 'first' bladder tumours, per hospital was 3 (25th, 75th: 2-5). In all, 58/179 (32.4%) hospitals utilised dedicated TURBT surgical lists.
Given the option of 'usually' 'sometimes' or 'never', 78/176 (44.3%) usually used bipolar, and 106/176 (60.2%) monopolar, resecting loop for TURBT. 38/176 (22%) hospitals used holmium and 9/176 (5.1%) used thulium laser 'usually' or 'sometimes'. Fractionated resection was performed 'usually' in most hospitals (118/176 (67%)), whilst 20/176 (11.4%) 'usually' performed en-bloc resection. Photodynamic Diagnosis assisted resection and narrow band imaging were used for first tumour resections in 36/176 (20.5%) and 45/176 (25.6%) respectively.
Regional trends were observed, examples of these are summarised in table 1.
Conclusions
There is observed variation in the organisation of services, technical performance and audit systems related to TURBT surgery across the world. It is not known how these differences impact outcomes, and this will be explored in the next phase of the RESECT study.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}